Related references
Note: Only part of the references are listed.Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL
Guangrong Lu et al.
CANCER BIOLOGY & THERAPY (2008)
Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells
Kuen-Feng Chen et al.
CANCER RESEARCH (2008)
Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody
Anil Shanker et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: A gene expression profiling study with implications for potential combination therapies
Xiaoxian Zhao et al.
LEUKEMIA RESEARCH (2008)
Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL
Feng-Ting Liu et al.
BLOOD (2008)
Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis
Jeffery A. Thorpe et al.
PROSTATE (2008)
Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition
William H. D. Hallett et al.
JOURNAL OF IMMUNOLOGY (2008)
TRAIL in cancer therapy:: present and future challenges
Delphine Merino et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2007)
Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor - Related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2
Mitchell R. Smith et al.
CLINICAL CANCER RESEARCH (2007)
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib
Jens Voortman et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis
Ronald Koschny et al.
CLINICAL CANCER RESEARCH (2007)
Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma
Patricia Gomez-Bougie et al.
CANCER RESEARCH (2007)
Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis
Hashem B. El-Serag et al.
GASTROENTEROLOGY (2007)
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells
Xiangguo Liu et al.
CANCER RESEARCH (2007)
Targeting death-inducing receptors in cancer therapy
K. Takeda et al.
ONCOGENE (2007)
NF-κB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs
Hamid Kashkar et al.
BLOOD (2007)
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death
Concetta Conticello et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis
Ernestina Saulle et al.
APOPTOSIS (2007)
The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines
Sandra J. Strauss et al.
CANCER RESEARCH (2007)
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window
Ronald Koschny et al.
HEPATOLOGY (2007)
Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells
Sanaz Khanbolooki et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function
Qin Wei et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: A novel method to potentiate natural killer cell tumor cytotoxicity
Andreas Lundqvist et al.
CANCER RESEARCH (2006)
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
M Cully et al.
NATURE REVIEWS CANCER (2006)
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
J Codony-Servat et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria
Katalin Nagy et al.
PATHOLOGY & ONCOLOGY RESEARCH (2006)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL
TM Ganten et al.
HEPATOLOGY (2005)
Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors
HB Zhu et al.
ONCOGENE (2005)
Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation
HB Zhu et al.
CANCER BIOLOGY & THERAPY (2005)
Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells
A Nencioni et al.
CLINICAL CANCER RESEARCH (2005)
Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells
LM Lashinger et al.
CANCER RESEARCH (2005)
Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma
K Nakanishi et al.
CANCER (2005)
3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells
SK Kulp et al.
CANCER RESEARCH (2004)
The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells
TR Johnson et al.
ONCOGENE (2003)
The proteasorne inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP
TJ Sayers et al.
BLOOD (2003)
Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma
TH Hu et al.
CANCER (2003)
Apo2L/TRAIL and its death and decoy receptors
HN LeBlanc et al.
CELL DEATH AND DIFFERENTIATION (2003)
NF-κB as a therapeutic target in cancer
RZ Orlowski et al.
TRENDS IN MOLECULAR MEDICINE (2002)
An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis
Y Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
TRAIL-induced apoptosis requires Bax-dependent mitochondria release of Smac/DIABLO
YB Deng et al.
GENES & DEVELOPMENT (2002)
CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-κB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells
A Trauzold et al.
ONCOGENE (2001)
Share Paper
